e-learning
resources
ERJ
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?
Loddenkemper Robert, Sotgiu Giovanni, Mitnick Carole D.
Source:
Eur Respir J 2012; 40: 9-11
Journal Issue:
July
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Loddenkemper Robert, Sotgiu Giovanni, Mitnick Carole D.. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. Eur Respir J 2012; 40: 9-11
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Multidrug resistant tuberculosis: clinical aspects and management
Source: Eur Respir J 2001; 18: Suppl. 33, 235s
Year: 2001
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Multidrug resistant pulmonary TB: Characteristics of drug resistance profiles of MBT in Ukraine
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Source: Eur Respir J 2013; 42: 1148-1150
Year: 2013
Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis
Source: Eur Respir J 2012; 39: 1511-1519
Year: 2012
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
Source: Eur Respir J 2013; 42: 1449-1453
Year: 2013
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia
Source: Eur Respir J 2012; 40: 133-142
Year: 2012
Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran
Source: Eur Respir J 2004; 24: Suppl. 48, 657s
Year: 2004
Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough?
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017
Year: 2017
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes
Source: Eur Respir J 2013; 42: 156-168
Year: 2013
Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
Source: Eur Respir J 2008; 31: 904-905
Year: 2008
MDR-TB management: what is new?
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012
Multidrug resistant tuberculosis in non HIV patients
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Multidrug resistance of
M. tuberculosis
and its infuence on treatment efficiency of new detected patients with pulmonary tuberculosis in penitentiary institutions of Belarus
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept